Survey of dotinurad use in hyperuricemic patients with impaired renal function -A retrospective observational study-

Shimazu keiji0 个研究点目标入组 500 人开始时间: 待定最近更新: 2025年3月17日

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 500
主要终点: Percentage of patients achieving a serum uric acid level of 6.0 mg/dL or less

暂无简介。

•Of the patients who were prescribed dotinurad at Osaka Saiseikai Nakatsu Hospital (hereafter referred to as "this hospital") during the study period, those patients could be classified into eGFR categories G1 to G5 at the start of dotinurad administration.
•Patients (of any gender) 20 years of age or older at the start of dotinurad treatment.

•Patients who visited our clinic after being started on dotinurad at another medical institution (patients who were already taking dotinurad at the time of their first visit to our clinic).
•Patients who indicated their intention not to participate by opting out.

Percentage of patients achieving a serum uric acid level of 6.0 mg/dL or less

时间窗: 12 months after the start of treatment

Percentage of patients achieving a serum uric acid level of 6.0 mg/dL or less at 12 months after the start of treatment with dotinurad

Serum uric acid levels for each of the 12 months(12 months before and after the start of treatment with dotinurad)
Serum uric acid level and its change(3, 6, and 12 months after the start of dotinurad administration)
Percentage of patients achieving serum uric acid levels of 6.0 mg/dL or less and 7.0 mg/dL or less(3, 6, and 12 months after the start of dotinurad treatment)
eGFR and its change(3, 6, and 12 months after the start of dotinurad treatment)
eGFR at 12 months(12 months before and after the start of treatment with dotinurad)

发起方

Shimazu keiji